Supervalu EVP joins NACDS board of directors
ALEXANDRIA, Va. An organization catering to the retail pharmacy industry has elected a new member to its board.
The National Association of Chain Drug Stores announced that Duncan Mac Naughton, EVP merchandising and marketing for Supervalu, was elected to the board of directors, effective Aug. 14. Mac Naughton will fill the position vacated by Kevin Tripp, who recently retired as Supervalu’s EVP of its retail Midwest division.
Mac Naughton will serve the remainder of the 2009-2010 term until April 2010, when the annual board of directors elections are held at the NACDS Annual Meeting.
Mac Naughton has a career of service within the supermarket industry. He has served on SUPERVALU’s executive team since joining the company in 2006 upon its acquisition of Albertsons, where Mac Naughton had served as executive vice president of merchandising. Prior to Albertsons, he served in key leadership roles at H-E-B and Kraft Foods.
“We are pleased to welcome Duncan to the NACDS Board of Directors,” said NACDS president and CEO Steve Anderson. “NACDS’ diverse membership is well-represented by the NACDS Board of Directors. Duncan brings leadership and expertise on behalf of the supermarket segment, and we look forward to working together to advance pharmacy as the face of neighborhood healthcare and to add value to NACDS’ engagement in front-end activities.”
Roadside Medical Clinic + Lab to open 11 new sites
LAS VEGAS Roadside Medical Clinic + Lab, which operates a network of retail health clinics for over-the-road professional truck drivers, announced on Thursday that emergency room physician Royce Brough has received licenses for 11 sites throughout six states.
Brough, a practicing emergency room physician with more than 35 years of experience, will be opening a location in Oklahoma City, Okla., within the next 90 days followed by Dallas in the first quarter 2010. The remaining sites, to be located in California, New Mexico, New Jersey and Indiana, will be open “as quickly as possible.”
“Keeping with our mission to deliver convenient healthcare to professional drivers coast to coast we are pleased to be working with Dr. Royce Brough to grow a national network of velocity through franchising and licensing,” stated Bob Perry, president of Roadside Medical Clinic + Lab and vice chair of the American Transportation Association Safety Management Council’s Health & Wellness Working Group. “Dr. Brough is an accomplished physician and we are fortunate to have him on board with Roadside Medical Clinic + Lab.”
Brough is also founder of The Brough Group and Hospital Physicians of America.
Roadside Medical Clinic + Lab began offering franchising and licensing opportunities within a limited number of markets in February 2009. Since then the company has secured sites in Tennessee, Arkansas, Illinois and Georgia.
Through an exclusive partnership with Pilot Travel Centers, the company provides cost-effective convenient care medical services including DOT physicals and compliance, wellness programs, sleep apnea studies and treatment and nutritional products for drivers. Pilot is the largest operator of truck stops in the United States with more than 300 locations in 41 states. Roadside Medical Clinic + Lab has planned for a total of 80 sites throughout the United States located exclusively at Pilot Travel Centers in order to meet the needs of the 4.2 million over-the-road professional drivers.
Bristol-Myers Squibb extends deadline for Medarex acquisition
NEW YORK Drug maker Bristol-Myers Squibb has extended its acquisition offer for a biotech company that uses a proprietary technology platform to develop treatments for chronic diseases, Bristol announced Thursday.
The New York-based pharmaceutical giant announced that its tender offer for Medarex would expire at midnight on Wednesday. It had originally been scheduled to expire Monday. Medarex develops monoclonal antibodies for cancer, inflammatory and autoimmune diseases using its UltiMAb technology.
Bristol said that more than 11.5 million shares of Medarex had been tendered and that Medarex shareholders would receive $16 per share upon the closing of the deal.